Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis
Objective: To review the evidence and compare the efficacy and safety of catechol-O-methyltransferase inhibitors (COMT-Is), dopamine agonists (DAs) and monoamine-oxidase B inhibitors (MAOB-Is) as adjunctive…Beta LFP Power Change After Levodopa Intake in Parkinson’s Disease Patients with Chronic Sensing-Enabled DBS Systems
Objective: To study the relationship between oscillatory beta activity in the subthalamic nucleus (STN) and the intake of dopaminergic medication in a group of Parkinson’s…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study
Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias
Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.
Objective: To investigate efficacy, tolerability, and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in Parkinson’s disease. Background: LECIG was introduced in 2019. The approval was based…Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.
Objective: To evaluate clinical impact of treatment (LCIG) infusion in patients with advanced PD. Background: Levodopa/carbidopa intestinal gel (LCIG) infusion has demonstrated more stable plasma…Risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: The present meta-analysis aims to find out association between risk of hallucinations and amantadine treatment in levodopa-induced dyskinesia (LID) patients with Parkinson’s disease (PD).…The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.
Objective: The aim of the present study was to analyze the response to levodopa in Parkinson´s disease (PD) patients with motor fluctuations followed up for…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 62
- Next Page »